The Dutch pension asset manager's Asia Pacific head of real estate says his team has just had one of its busiest years ever and that 2021 is looking similarly promising.
MBKÆs offer has been accepted by shareholders who hold a combined 28.53% of the total issued share capital of AsiaPharm, ABN Amro said in an announcement. AsiaPharm shareholders have until March 31 to decide whether to accept MBK's offer, which values the firm at S$357.4 million ($259 million) after MBK extended the offer deadline by a week on Monday.
ABN Amro says MBK does not intend to revise its offer price of S$0.725 per share for AsiaPharm, but reserves the right to revise the offer price ôif a competitive situation arises in relation to the offerö.
Templeton Asset Management, meanwhile, is likewise standing firm on its opposition to the impending deal.
ôTempleton is standing by its stance that the current offer price is undervalued, especially when you take into consideration the longer term prospects of the company,ö a company spokesperson says. ôWeÆre standing by our view that ChinaÆs pharmaceutical sector has bright prospects.ö
Templeton is a minority shareholder in AsiaPharm and is opposing the management buyout offer made in early-February by MBK for the Chinese pharmaceutical company. It opposes on the grounds that it believes the offer price is undervalued by at least 50% and fails to take into consideration potential earnings over a three- to five-year period.
Templeton manages the Templeton Strategic Emerging Markets Fund II, which holds a 4% share in AsiaPharm. Templeton has said that it is not convinced by the cash offer by Lu Ye Pharmaceutical Investment û controlled by private equity firm MBK Partners û to acquire all the issued and paid-up ordinary shares of AsiaPharm.
MBKÆs offer for AsiaPharm will eventually result in the companyÆs delisting from the Singapore stock exchange. MBK Partners was founded by five ex-Carlyle executives led by Michael Kim, who previously headed CarlyleÆs Asia practice.
Mark Mobius, Templeton president and principal portfolio manager, has vowed to vote against the buyout and is enlisting the support of fellow minority shareholders, including US-based Pope Asset Management and UK firm Martin Currie Investment Management to reject the deal.
AsiaPharm is a specialty pharmaceutical group in China which started operations in 1994. It is engaged in the production and sale of drugs and formulations for medicines for orthopaedics, neurology, gastroenterology and hepatology and also provides contract research services. AsiaPharm has a manufacturing facility in Yantai in the northeastern Shandong province in China and a distribution network of 35 sales offices covering 30 provinces.
Malaysia's Armed Forces Fund hires new CEO; Canada's Omers appoints Asia capital markets managing director; HSBC Asset Management creates alternatives unit, appoints CIO as its head; Bank of Singapore names global wealth head; Aware Super hires IFA head; Hong Kong names acting head for MPFA; Schroders adding to Asia ESG headcount; and more.
The French fund house becomes the world’s largest responsible asset manager to help asset owners implement sustainable investing, underlining its serious commitment to ESG.
The long-waited infrastructure Reits have finally arrived in China and, while experts see a slow start with hurdles ahead, they say it will later move to a 'big bang'.
AsianInvestor reveals the second half of the standout funds in our latest awards, including equity funds, the top Reit and the best smart beta vehicle.